WO1999034218A1 - Procede de depistage de la maladie de crohn et kit d'analyse prevu a cet effet - Google Patents
Procede de depistage de la maladie de crohn et kit d'analyse prevu a cet effet Download PDFInfo
- Publication number
- WO1999034218A1 WO1999034218A1 PCT/JP1998/005960 JP9805960W WO9934218A1 WO 1999034218 A1 WO1999034218 A1 WO 1999034218A1 JP 9805960 W JP9805960 W JP 9805960W WO 9934218 A1 WO9934218 A1 WO 9934218A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amylase
- disease
- crohn
- immunoglobulin
- enzyme
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/40—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving amylase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
Definitions
- the present invention relates to a method for testing Crohn's disease and a kit for testing. More specifically, the present invention relates to a Crohn's disease test method and a test kit which can be easily and rapidly carried out by immunological or enzymatic methods in the clinical test field.
- Conventional technology relates to a Crohn's disease test method and a test kit which can be easily and rapidly carried out by immunological or enzymatic methods in the clinical test field.
- Crohn's disease and ulcerative colitis are classified as idiopathic inflammatory bowel diseases for unknown reasons and are identified as intractable diseases of the Ministry of Health and Welfare.
- the diagnosis is made in accordance with the diagnostic criteria (draft) prepared by the Research Group for Inflammatory Intestinal Intractable Diseases of the Ministry of Health and Welfare.
- the diagnostic criteria (draft) prepared by the Research Group for Inflammatory Intestinal Intractable Diseases of the Ministry of Health and Welfare.
- clinical findings, angiography, endoscopy, and histology are combined.
- some cases are difficult to diagnose using these methods. In particular, it is often difficult to distinguish Crohn's disease from ulcerative colitis.
- gastrointestinal angiography and endoscopy which are the main diagnostic tools, often involve the physical and mental distress of patients, and require skilled physicians. Therefore, there is a worldwide need for a simple, rapid, and highly accurate specific clinical test method for diagnosing Crohn's disease and ulcerative colitis.
- Anti-neutrophil antibody (Targan, S., et al .: Gastroenterology, 96, A505, 1989) ⁇ Anti-small intestinal antibody (Bagchi, S., et al .: Cl in . Exp. Immunol, 55, 44-48, 1984), while serum from patients with ulcerative colitis contains anti-tropomyosin antibodies (Das, Kn., Et al .: J. Immunol., 150, 2487-). 2493, 1993) ⁇ Anti-casein antibodies (Knoflach, P., et al .: Gastroenterology, 92, 479-485, 1987) or the presence of anti-mucin antibodies have been reported.
- An object of the present invention is to provide a simple, rapid, and highly accurate clinical test method for diagnosing Crohn's disease and ulcerative colitis in mammals, particularly humans, and a test kit for use in the method. .
- the first aspect of the present invention is a method for detecting Crohn's disease, which comprises detecting the presence of an immunoglobulin that reacts with amylase in a sample.
- the second aspect of the present invention is a method for testing for Crohn's disease, which comprises detecting the presence of immunoglobulin that reacts with amylase in a sample by an immunological assay or an enzymatic assay.
- the third aspect of the present invention is to provide an immunoglobulin which reacts with amylase in a sample with a support. After reacting with the amylase immobilized on the sample, the labeled product of the substance that reacts with the immunoglobulin that reacts with the amylase is reacted, and the amount of the reaction product is measured.
- a method for detecting Crohn's disease which comprises detecting the presence of immunoglobulin that reacts with amylase.
- a fourth aspect of the present invention is that an immunoglobulin that reacts with amylase in a sample is reacted with amylase, and then the enzymatic measurement method includes a step of measuring the amylase activity of the reaction product.
- This is a method for detecting Crohn's disease, which comprises detecting the presence of immunoglobulin that reacts with amylase.
- a fifth aspect of the present invention is the method for testing for Crohn's disease, wherein the amylase is bushu's amylase or Pseudoamylase.
- a sixth aspect of the present invention is a kit for testing for Crohn's disease, which comprises detecting an amylase-reactive immunoglobulin in a specimen, comprising an amylase and a reagent for measuring amylase activity or a reagent for measuring labeled enzyme activity.
- a seventh aspect of the present invention is a support on which amylase is immobilized; an enzyme-labeled anti-human IgG antibody, an enzyme-labeled anti-human IgA antibody, an enzyme-labeled protein A, an enzyme-labeled protein G, and an enzyme-labeled protein.
- An eighth aspect of the present invention is the above-mentioned test kit for Crohn's disease, wherein the amylase is bushu's amylase or Pseudoamylase.
- FIG. 9 is a scatter diagram showing the results of detection of the presence of immunoglobulin that reacts with busha-amylase in serum and serum from normal subjects (Normal, 30 cases). *, Indicates the statistically significant difference between patients with Crohn's disease and patients with ulcerative colitis, stomach ulcer, duodenal ulcer, macroamylaseemia and other diseases and healthy subjects (*: 0.05, **: p ⁇ 0.01). 0.167 is the cut-off value determined from the measured value of the serum of a healthy subject.
- FIG. 4 is a scatter diagram showing the results of detection of the presence of immunoglobulin that reacts with p-amylase in the serum of normal subjects (Normal, 18 cases). *, Indicates a statistically significant difference between Crohn's disease patients and ulcerative colitis patients, gastric ulcers, duodenal ulcers, macroamylasemic and other diseases and healthy subjects (*: p ⁇ 0.05, **: p ⁇ 0.01). 0.105 is the cut-off value determined from the measured value of the serum of a healthy individual.
- the present inventors have sought an ideal test method for Crohn's disease in mammals, especially humans, and have conducted epidemiological, immunological, and biochemical studies, and have found that they react with amylase in the blood of Crohn's disease patients. Found that the amount of immunoglobulin The invention has been completed.
- the present invention provides a method for detecting Crohn's disease, which comprises detecting the presence of immunoglobulin that reacts with amylase in a sample using amylase.
- an immunological assay such as an enzyme immunoassay, or a t or deviation of an enzymatic assay may be used.
- an immunological assay such as an enzyme immunoassay, or a t or deviation of an enzymatic assay may be used.
- the amylase used in the present invention a different type of amylase is used.
- any non-human amylase other than human may be used.
- amylase derived from edible animals that is, amylase derived from bush, sea bream, chicken, chicken, etc., is preferable, and amylase derived from bush or sea bream is particularly preferably used.
- the present invention will be described with respect to a method for testing human Crohn's disease, but the present invention is not limited thereto.
- a specimen to be subjected to the method of the present invention most of human body fluids can be used, and for example, whole blood, serum, plasma, urine, saliva and the like are preferable. Particularly preferred is serum or plasma of a patient.
- the immunoassay any method may be used, but an enzyme immunoassay, an immunochromatography and the like are preferable. In each method, immunoglobulin that reacts with amylase in the sample is reacted with amylase immobilized on a support, and then a labeled product of a substance that reacts with the immunoglobulin that reacts with the amylase is reacted. Measuring the labeled amount of the substance.
- a labeled amount of a reaction product is measured by enzyme activity using an enzyme-labeled product.
- Imnochromat In the graphic method, a labeled amount of a reaction product is measured based on a colored amount using a labeled colored particle.
- an enzyme immunoassay which can easily quantify the labeling amount of a reaction product, that is, the amount of immunoglobulin which reacts with amylase in a sample is preferably used.
- an immunoglobulin that reacts with amylase in a sample is reacted with amylase immobilized on a support, and then a substance that reacts with immunoglobulin that reacts with the amylase, preferably an anti-human immunoglobulin antibody
- a method comprising reacting an enzyme-labeled product of protein A, protein G, or jackalin and measuring the amount of the reaction product labeled by the enzyme activity is suitable.
- the support for example, plastic or glass such as polystyrene resin, polycarbonate resin, silicone resin, and nylon resin are suitable.
- the method of fixing the support hair mirror may be physical adsorption or chemical bonding.
- a labeling enzyme peroxidase, 5-galactosidase and alkaline phosphatase are suitable.
- an enzymatic measurement method a method based on the principle that immunoglobulin that reacts with amylase in a sample inhibits amylase activity is used.
- the simplest method for measuring the degree of inhibition of the amylase activity is the in vitro reaction method. That is, an amylase solution of a known concentration is mixed 1: 1 with a sample in a test tube, and after standing for a certain period of time, the amylase activity of the mixture is measured by a known activity measurement method (Tholla, JA, et al: The Enzyme (3rd ed. ), 5, 115-189, 1971).
- blood using a synthetic substrate such as 4-ditrophenyl-1-maltopenoside ⁇ p-l-trophenylbenzyl- ⁇ -maltopene-oside is used.
- a medium amylase measurement kit is preferably used. The degree of inhibition of the amylase activity is calculated by subtracting the amylase activity of the 2-fold diluted sample and the amylase activity of the 2-fold diluted amylase solution, respectively, from the amylase activity of the mixture.
- the immunoglobulin which reacts with amylase in a sample is reacted with amylase, then separated from human amylase using a serum protein separation carrier, and the degree of inhibition of the amylase activity of the reaction product is determined.
- a method including a step of measuring is also preferably used.
- Suitable carriers for separating serum proteins include cellulose acetate membranes, agarose gels, polyacrylamide gels, and dextran gels.
- an electrophoresis method, a liquid chromatography method, or the like is used as the separation method on the carrier.
- the electrophoresis method is preferred from the viewpoint of simplicity and speed.
- the present invention further provides a kit for detecting Crohn's disease, which comprises detecting an amylase-reactive immunoglobulin in a sample, comprising an amylase and a reagent for measuring amylase activity or a reagent for measuring labeled enzyme activity. Is what you do.
- the test kit of the present invention comprises an amylase-immobilized support; an enzyme-labeled anti-human IgG antibody, and an enzyme-labeled anti-human IgA antibody.
- Body an enzyme-labeled product selected from the group consisting of enzyme-labeled protein A, enzyme-labeled protein G and enzyme-labeled jackpotrin; and a reagent for measuring a labeled enzyme activity.
- the test kit of the present invention contains amylase and a reagent for measuring amylase activity.
- the test kit of the present invention comprises, in addition to amylase and bull starch, a reagent for measuring amylase activity, a cellulose acetate membrane as a carrier for separating serum proteins. Including.
- the kit for testing Crohn's disease of the present invention can further contain a buffer, a standard serum, and the like.
- a buffer a standard serum
- the present invention will be described in detail with reference to examples, but the present invention is not limited thereto.
- Each of the 96-well microplates was prepared by diluting Buena's Tenamirase (Sigma, A6225) diluted to 10 ⁇ g / ml with phosphate buffered saline (PBS). Then, 0.2 ml was added to each of the pellets, and the mixture was reacted at 4 ° C. After the reaction, the solution in each well was removed, 0.25 ml of PBS was added for washing, and the solution was removed after stirring. After repeating this washing operation three times, 0.25 ml of PBS containing 0.1% skim milk was added as a masking reagent, and the mixture was incubated at 37 ° C for 1 hour. After the masking, the solution in each well was removed, 0.25 ml of PBS containing 0.1% NaN 3 and 0.1% skim milk was added to each well as a stock solution, and the solution was stored at 4 ° C.
- Buena's Tenamirase Sigma, A6225
- PBS phosphate buffered
- the sandwich method was used to detect the presence of immunoglobulin that reacts with human amylase in human serum. That is, after removing the preservation solution from the microplate plate with the immobilized bush and amylase prepared above, the test serum or plasma, which had been diluted 80-fold with PBS containing 0.05% skim milk in advance, was added to each well for 0.2 times. After adding for 1 minute, the mixture was stirred for about 1 minute with a microplate mixer, and reacted at 37 ° C for 1 hour. After removing the liquid in each well, the wells were washed three times with 0.25 ml of PBS containing 0.05% Tween20.
- a peroxidase-labeled anti-human IgG antibody was diluted to an optimum concentration, 0.2 ml was added to each gel, and the reaction was performed again at 37 ° C for 1 hour. After the reaction, remove the solution and wash again. After completely removing the solution in each well, add 0.2 ml of a substrate solution (1.5 mg / ml o-phenylenediamine aqueous solution with 0.01% hydrogen peroxide) and add room temperature. For 10 minutes. The reaction was stopped by adding 0.05 ml of 3.5 N sulfuric acid to each well. The plate after the reaction was stopped was measured for absorbance (absorbance at 492 nm-absorbance at 630 nm) using a colorimeter for microplate (manufactured by BioRad).
- Example 1 shows the serum of patients with Crohn's disease (75 cases), ulcerative colitis (84 cases), gastric ulcer, duodenal ulcer, macroamylaseemia and other diseases (48 cases) and healthy subjects (30 cases).
- the presence of immunoglobulin that reacts with bush amylase was detected using the indicated method.
- the results are shown as a scatter diagram in FIG. Each point in the figure is the average of three measurements. Based on this result, a significant difference test was performed between Crohn's disease patients and ulcerative colitis patients, other disease patients, and healthy subjects. Globulin abundance was significantly higher.
- the degree of inhibition of amylase activity was calculated by (activity of mixed solution) / (activity of 2-fold diluted test serum) / (activity of 2-fold diluted busur-rouramylase solution) and expressed as inactivation activity.
- Serum of patients with other diseases such as Crohn's disease (86 cases), ulcerative colitis (86 cases), gastrointestinal disease, liver disease, and healthy subjects (25 cases) was measured by this measurement method.
- the activity of the serum of healthy volunteers to inactivate amylase was in the range of 0 to 30 units / 1.
- Tris' borate buffer pH 9.1 (Helena Research Labs., Titan, trade name)
- use Apriquet Ichiyo to apply Of a test serum or physiological saline (control) to which was added at about 600 units / ml was applied.
- the electrophoresis buffer used was 0.26 M Tris-borate buffer (pH 9.1) on the anode side, and Veronal buffer (pH 8.6) on the cathode side. Electrophoresis was performed at 120 V for 2 hours.
- Example 3 Detection of presence of immunoglobulin that reacts with blood amylase in blood by enzyme immunoassay
- phosphate buffered saline PBS
- a plate with an immobilized calcium amylase was prepared in the same manner as in Example 1, and measurement was performed using human serum as a sample.
- the immunoglobulin that reacts with cis-amylase is based on the cut-off value (0.104, mean value + 2 ⁇ standard deviation) set from the mean value (0.052) and the standard deviation (0.026) of the serum serum values of healthy subjects. Comparing the number of positive cases, there were only 19 cases of Crohn's disease, and none were found in other diseases. These results indicate that the detection of the presence of immunoglobulin that reacts with serum calcium amylase can be used for differential diagnosis of Crohn's disease. Industrial applicability
- the present invention provides a method for detecting Crohn's disease characterized by detecting the presence of immunoglobulin that reacts with amylase in blood by an immunoassay or an enzymatic assay using amylase. It provides an inspection kit. As is clear from the examples, the use of the test method and test kit of the present invention enables simple and rapid diagnosis of Kuhn's disease, especially differential diagnosis from ulcerative colitis.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Rehabilitation Therapy (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Photoreceptors In Electrophotography (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU16908/99A AU1690899A (en) | 1997-12-26 | 1998-12-25 | Method for testing crohn's disease and testing kit therefor |
JP2000526818A JP4274693B2 (ja) | 1997-12-26 | 1998-12-25 | クローン病の検査方法及び検査用キット |
DE69835620T DE69835620D1 (de) | 1997-12-26 | 1998-12-25 | Verfahren zum testen auf morbus crohn und testkit dafür |
EP98961604A EP1052511B1 (en) | 1997-12-26 | 1998-12-25 | Method for testing crohn's disease and testing kit therefor |
US09/604,275 US6777197B1 (en) | 1997-12-26 | 2000-06-26 | Method and test kit for measuring immunoglobulins reactive with amylase as indication of crohn's disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9/366837 | 1997-12-26 | ||
JP9366837A JPH11190734A (ja) | 1997-12-26 | 1997-12-26 | クローン病の検査方法および検査用キット |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/604,275 Continuation US6777197B1 (en) | 1997-12-26 | 2000-06-26 | Method and test kit for measuring immunoglobulins reactive with amylase as indication of crohn's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999034218A1 true WO1999034218A1 (fr) | 1999-07-08 |
Family
ID=18487806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/005960 WO1999034218A1 (fr) | 1997-12-26 | 1998-12-25 | Procede de depistage de la maladie de crohn et kit d'analyse prevu a cet effet |
Country Status (7)
Country | Link |
---|---|
US (1) | US6777197B1 (ja) |
EP (1) | EP1052511B1 (ja) |
JP (2) | JPH11190734A (ja) |
AT (1) | ATE336724T1 (ja) |
AU (1) | AU1690899A (ja) |
DE (1) | DE69835620D1 (ja) |
WO (1) | WO1999034218A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007136001A1 (ja) * | 2006-05-19 | 2007-11-29 | Osaka University | 炎症性腸疾患の鑑別判断方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002088175A1 (fr) * | 2001-04-24 | 2002-11-07 | Otsuka Pharmaceutical Co., Ltd. | Peptide de liaison a des anticorps de la maladie de crohn et methode d'examen de ladite maladie |
US20080057386A1 (en) * | 2002-10-15 | 2008-03-06 | Polyplus Battery Company | Ionically conductive membranes for protection of active metal anodes and battery cells |
CA2508136A1 (en) | 2002-12-09 | 2004-06-24 | Ajinomoto Co., Inc. | Apparatus and method for processing information concerning biological condition, system, program and recording medium for managing information concerning biological condition |
EP1862797A4 (en) * | 2005-03-16 | 2009-09-16 | Ajinomoto Kk | DEVICE, METHOD, SYSTEM AND PROGRAM FOR EVALUATING BIOLOGICAL STATES, DEVICE, METHOD AND PROGRAM FOR GENERATING AN EVALUATION FUNCTION AND RECORDING MEDIUM |
CN101351710B (zh) * | 2005-04-04 | 2013-06-05 | 生物基因Idecma公司 | 评价对治疗性蛋白质的免疫应答的方法和产品 |
JP4577083B2 (ja) * | 2005-04-28 | 2010-11-10 | 味の素株式会社 | クローン病の診断方法 |
EP2124059A4 (en) | 2007-01-24 | 2010-10-20 | Ajinomoto Kk | METHOD OF EVALUATING IBD, AMINO-SURFACE DATA PROCESSING DEVICE, AMINO-SITE DATA PROCESSING METHOD, AMINO-SURFACE DATA PROCESSING SYSTEM, AMINO-SITE DATA PROCESSING PROGRAM, AND RECORDING MEDIUM |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4948723A (en) * | 1987-01-16 | 1990-08-14 | Bioscience International, Inc. | Method of diagnosis and severity-assessment of pancreatic disease |
JPH0528500A (ja) * | 1991-07-23 | 1993-02-05 | Matsushita Electric Ind Co Ltd | デイスク再生装置 |
US6066322A (en) * | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
US5712097A (en) * | 1996-01-19 | 1998-01-27 | The Johns Hopkins University School Of Medicine | Tumor suppressor gene, DPC4 |
JPH09328500A (ja) * | 1996-04-10 | 1997-12-22 | Wako Pure Chem Ind Ltd | 膵型α−アミラーゼアイソザイムの測定法 |
-
1997
- 1997-12-26 JP JP9366837A patent/JPH11190734A/ja active Pending
-
1998
- 1998-12-25 JP JP2000526818A patent/JP4274693B2/ja not_active Expired - Fee Related
- 1998-12-25 DE DE69835620T patent/DE69835620D1/de not_active Expired - Lifetime
- 1998-12-25 WO PCT/JP1998/005960 patent/WO1999034218A1/ja active IP Right Grant
- 1998-12-25 AT AT98961604T patent/ATE336724T1/de not_active IP Right Cessation
- 1998-12-25 AU AU16908/99A patent/AU1690899A/en not_active Abandoned
- 1998-12-25 EP EP98961604A patent/EP1052511B1/en not_active Expired - Lifetime
-
2000
- 2000-06-26 US US09/604,275 patent/US6777197B1/en not_active Expired - Fee Related
Non-Patent Citations (3)
Title |
---|
HARAGUCHI M., "A Case of Crohn's Disease with Hyperamylasemia", Vol. 40, No. 1, (1987), p. 45-49, XP002922215. * |
HEGNHOJ J., ET AL.: "PANCREATIC FUNCTION IN CROHN'S DISEASE.", GUT, BRITISH MEDICAL ASSOCIATION, LONDON,, UK, vol. 31., 1 January 1990 (1990-01-01), UK, pages 1076 - 1079., XP002922214, ISSN: 0017-5749, DOI: 10.1136/gut.31.9.1076 * |
STURDEVANT R. A. L., ET AL.: "AZATHIOPRINE-RELATED PANCREATITIS IN PATIENTS WITH CROHN'S DISEASE.", GASTROENTEROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 77., no. 04., 1 October 1979 (1979-10-01), AMSTERDAM, NL, pages 883 - 886., XP002922216, ISSN: 0016-5085 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007136001A1 (ja) * | 2006-05-19 | 2007-11-29 | Osaka University | 炎症性腸疾患の鑑別判断方法 |
US8043832B2 (en) | 2006-05-19 | 2011-10-25 | Osaka University | Method for determination of inflammatory bowel disease |
JP4973885B2 (ja) * | 2006-05-19 | 2012-07-11 | 国立大学法人大阪大学 | 炎症性腸疾患の鑑別判断方法 |
Also Published As
Publication number | Publication date |
---|---|
AU1690899A (en) | 1999-07-19 |
EP1052511A1 (en) | 2000-11-15 |
ATE336724T1 (de) | 2006-09-15 |
JPH11190734A (ja) | 1999-07-13 |
DE69835620D1 (de) | 2006-09-28 |
US6777197B1 (en) | 2004-08-17 |
EP1052511A4 (en) | 2004-10-13 |
JP4274693B2 (ja) | 2009-06-10 |
EP1052511B1 (en) | 2006-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0615129B1 (en) | Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis or primary sclerosing cholangitis | |
US4748110A (en) | Immunoassay for HTLV-III antigens | |
JP3630689B2 (ja) | 抗ポリマー抗体の検出方法およびシリコーン関連疾患(srd)の診断を援助するのに有用な診断試験キット | |
CA1256025A (en) | Immuno-chemical measurement process for haptens and proteins | |
EP0345462A2 (en) | Immunoassay for HIV-1 antigens using F(AB')2 fragments as probe | |
CA1148858A (en) | Determination of immunoglobulins | |
WO1999034218A1 (fr) | Procede de depistage de la maladie de crohn et kit d'analyse prevu a cet effet | |
CA2361000C (en) | Urinary trypsin inhibitor to diagnose aids | |
CA1295551C (en) | Immunoassay for antibodies to htlv-iii | |
EP0398292B1 (en) | Diagnostic composition for rheumatoid arthritis | |
US20040115750A1 (en) | Method and means for detecting gluten-induced diseases | |
US5175083A (en) | Immunoassay for the quantitation of human C4 gene products | |
JPH07248329A (ja) | 結核感染症検査用膜およびこれを用いる結核感染症関連抗体の検出方法 | |
EP1222210A1 (en) | Immunological assay for detection of antibodies in celiac disease | |
JP2002071694A (ja) | 炎症性腸疾患の検査方法及び検査用キット | |
EP0726961A1 (en) | Diagnosis of mental disorders | |
JP2003107088A (ja) | 播種性血管内凝固症候群及びその発症前段階を検出する方法 | |
Bini et al. | Measurement of plasmin-antiplasmin complex in plasma. A comparison of latex agglutination, latex agglutination inhibition and hemagglutination inhibition tests | |
JPH02173569A (ja) | ヒト組織プラスミノーゲンアクチベーター・ヒトプラスミノーゲンアクチベーターインヒビター複合体の測定方法及び測定キット | |
EP0323785A1 (en) | IGG rheumatoid factor test | |
WO1996036879A1 (fr) | Procede de dosage d'antigenes associes a des maladies auto-immunes | |
TEST | ImmunoWELL™ | |
JPH11142407A (ja) | 抗fkbp12自己抗体の検出方法 | |
WO1991008487A1 (en) | Method of determining anti-xanthine oxidase antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN IL JP KR NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998961604 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998961604 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998961604 Country of ref document: EP |